Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725083 | 0.99 | ALDH1A1 (0.54) | ALDH1A1HPGDHSD17B10CNR2CA12 | |
| SCHEMBL5725098 | 0.99 | ALDH1A1 (0.54) | ALDH1A1HPGDHSD17B10CNR2CA12 | |
| SCHEMBL5724723 | 0.96 | ALDH1A1 (0.56) | ALDH1A1HPGDHSD17B10CNR2CA12 | |
| SCHEMBL8530599 | 0.93 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10CNR2CA12 | |
| SCHEMBL5726215 | 0.93 | CA12 (0.50) | ALDH1A1HPGDHSD17B10CNR2CA12 | |
| SCHEMBL5725090 | 0.89 | CNR2 (0.49) | CNR2CA12CA1CA2CA4 | |
| SCHEMBL5725536 | 0.88 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10CNR2 | |
| SCHEMBL5725451 | 0.87 | CA12 (0.52) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL5043556 | 0.87 | CNR2 (0.53) | ALDH1A1HPGDHSD17B10CNR2 | |
| SCHEMBL5724887 | 0.87 | PLA2G4B (0.55) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951282-B1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER (US) | 2008-04-02 | — | — | EP | claimed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | claimed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | claimed |
| CN-1599605-A | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PFIZER PROD INC (US) | 2005-03-23 | — | — | CN | claimed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | claimed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | claimed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | claimed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| JP-2000507961-A | — | — | 2000-06-27 | — | — | JP | claimed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | claimed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| CN-100439366-C | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | ALDH1A1 2216/4885HPGD 20/4885HSD17B10 1860/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | ALDH1A1 2216/4885HPGD 20/4885HSD17B10 1860/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | ALDH1A1 3721/4885HPGD 280/4885HSD17B10 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.